Altimmune, Inc.

$ALT gapped up today on news that in a Phase 2 trial, its drug Pemvidutide showed success in inducing weight loss. The results showed that more than 50% of enrollees achieved at least 15% weight loss, while more than 30% of people achieved at least 20% weight loss on certain doses.